Company says it estimates initial annual revenue of approximately $1 million ORLANDO, Fla. -- Sequiam Corporation, through its wholly-owned subsidiary Sequiam Biometrics, Inc.
BioTime and OncoCyte Corporation Publish Data on the Gene as a Marker and Potential Diagnostic for a Wide Array of Human Cancers BioTime, Inc.Peter Garcia, 510-521-3390 ext. 367Chief Financial ...
On August 2, 2018, BioTime Inc. (NYSE: BTX; $2.31; market capitalization: $293 million) announced results for 2Q18. BioTime primary clinical programs Renevia and OpRegen progressed on research and ...
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement with ...
Stem cell technology developer Cell Targeting has sold its assets to BioTime (AMEX:BTX) in a deal worth about $2.3 million. BioTime will pay $250,000 in cash as well as 262,000 shares of BioTime’s ...
BioTime Inc. picked up 400 patents and applications plus other intellectual property dealing with human embryonic stem cells from Geron Inc. BioTime Inc. picked up 400 patents and applications plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback